Key result
Cochrane protocol outlines planned systematic review of statins versus placebo in adults with schizophrenia.
Why the study?
Do HMG-CoA reductase inhibitors (statins) improve outcomes compared to placebo in adults with schizophrenia?
Do HMG-CoA reductase inhibitors (statins) improve outcomes compared to placebo in adults with schizophrenia?
Answers are grounded in this paper and cite their sources.
This protocol outlines a planned Cochrane Review to assess the benefits and harms of statins versus placebo in adults with schizophrenia.
OBJECTIVES: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of HMG-CoA reductase inhibitors (statins) compared with placebo for schizophrenia in adults.
No takes yet. Share an insight, caveat, or question.
Saishoji et al. (2025) studied this question. HMG-CoA reductase inhibitors (statins) will be evaluated against placebo to determine their benefits and harms for adults with schizophrenia in a Cochrane Review protocol.
Synapse has enriched 10 related papers. Consider them for comparative context: